Third Peoples Hospital of Dalian

Dalian, China

Third Peoples Hospital of Dalian

Dalian, China

Time filter

Source Type

Qu M.-H.,Third Peoples Hospital of Dalian | Zeng R.-F.,Sun Yat Sen University | Fang S.,Sun Yat Sen University | Dai Q.-S.,Sun Yat Sen University | And 2 more authors.
International Journal of Pharmaceutics | Year: 2014

Combination of more than one therapeutic strategy is the standard treatment in clinics. Co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) within a nanoparticulate system will suppress the tumor growth. In the present study, docetaxel (DTX) and BCL-2 siRNA was incorporated in a PEGylated liposome to systemically deliver in a lung cancer model (A549). The resulting nanoparticle (lipo-DTX/siRNA) was stable and exhibited a sustained release profile. The co-delivery of therapeutic moieties inhibited the cell proliferation (A549 and H226) in a time-dependent manner. Moreover, the co-delivery system of DTX and siRNA exhibited a remarkable apoptosis of cancer cells with elevated levels of caspase 3/7 activity (apoptosis markers). Cell cycle analysis further showed remarkable increase in sub-G0/G1 phase, indicating increasing hypodiploids or apoptotic cells. Pharmacokinetic study showed a long circulating profile for DTX from lipo-DTX/siRNA system facilitating the passive tumor targeting. In vivo antitumor study on A549 cell bearing xenograft tumor model exhibited a remarkable tumor regression profile for lipo-DTX/siRNA with 100% survival rate. The favorable tumor inhibition response was attributed to the synergistic effect of DTX potency and MDR reversing ability of BCL-2 siRNA in the tumor mass. Overall, experimental results suggest that co-delivery of DTX and siRNA could be promising approach in the treatment of lung cancers. © 2014 Published by Elsevier B.V.


Fan Z.,Third Peoples Hospital of Dalian | Tian X.F.,Dalian Medical University | Tang S.X.,Dalian University | Zhang Y.Y.,Third Peoples Hospital of Dalian | And 2 more authors.
Medicine (United States) | Year: 2014

A liposarcoma is the most common type of soft tissue sarcoma, and most liposarcomas are malignant. The extremities are the most common site for liposarcomas. There are 5 histologic types of liposarcoma, as follows: well differentiated; myxoid; round cell; pleomorphic; and dedifferentiated. Myxoid liposarcomas (MLSs) represent a subgroup of liposarcomas. There has been no report of MLSs in the abdominal wall.We report a rare case of a MLS of a 43-year-old male who presented with tensile force on the abdominal wall. Computed tomography (CT) found a tumor in abdominal wall. There was no other abnormal symptom and the laboratory testing was also unusual.At last, the tumor was successfully excised, which was diagnosed MLSs in pathology. Following standard principles, after complete excision, the patient received radiotherapy. The patient was followed up for 8 month and no disease recurrence was identified.MLSs are rarely seen in the clinic, irrespective of the presenting signs, but also based on histologic features. The aim of this report was to present the differential diagnosis of an abdominal wall mass, and to remind us of MLSs. Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Fan Z.,Third Peoples Hospital of Dalian | Tian X.,Dalian Medical University | Pan J.,Third Peoples Hospital of Dalian | Li Y.,Liaoning Cancer Hospital and Institute | And 2 more authors.
Medicine (United States) | Year: 2015

ABSTRACT: Henoch-Schonlein purpura (HSP) is a self-limited autoimmune disease, the cause of which is not clear. Gastrointestinal involvement is often the main symptom of HSP. We report an unusual and rare case in a patient who was diagnosed with HSP. This is the second report of terminal ileitis induced by HSP that presented as acute appendicitis.We report a 21-year-old man who presented with right lower abdominal pain, and was diagnosed with acute appendicitis. Terminal ileitis was diagnosed intraoperatively, and when a rash occurred postoperatively, the final diagnosis was HSP.When the rash occurred, HSP was diagnosed and methylprednisolone was administered for 5 days.The diagnosis of HSP is difficult to establish, especially when the purpura occurs after gastrointestinal involvement; thus, abdominal pain should not be ignored and HSP should be considered. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.


Fan Z.,Third Peoples Hospital of Dalian | Jing H.,Dalian Medical University | Yao J.,Dalian Medical University | Li Y.,Liaoning Cancer Hospital and Institute | And 6 more authors.
Oxidative Medicine and Cellular Longevity | Year: 2014

Objective. In this study, we investigated the protective effect and mechanism of curcumin on a rat model of intestinal ischemia/reperfusion (I/R), which induces an acute liver lesion. Methods. Curcumin was injected into rats in the curcumin groups through left femoral vein. The same volume of vehicle (0.9% normal saline) was injected into shamand I/R groups. Blood and liver tissue were gathered for serological and histopathological determination. Results. Intestinal I/R led to severe liver injurymanifested as a significant increase in serum AST and ALT levels; all of those were reduced by treatment with curcumin. Simultaneously, the activity of SOD in liver decreased after intestinal I/R, which was increased by curcumin treatment. On the other hand, curcumin reduced MPO activity of liver tissue, as well as serumIL-6 and TNF-α levels observably.This is in parallel with the decreased level of liver intercellular cell adhesion molecule-1 (ICAM-1) and nuclear factor-κB (NF-κB) expression. Conclusion. Our findings suggest that curcumin treatment attenuates liver lesion induced by intestinal I/R, attributable to the antioxidative and anti-inflammatory effect via inhibition of the NF-κB pathway. Copyright © 2014 Zhe Fan et al.


Lu W.,Dalian Medical University | Wei H.,Dalian Medical University | Li M.,Dalian Medical University | Wang H.,Third Peoples Hospital of Dalian | And 3 more authors.
Molecular Medicine Reports | Year: 2015

Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth factor receptor, is currently considered to be the strategy with the most potential for the treatment of gastric cancer due to the low frequency of KRAS mutations in patients with gastric cancer. However, the therapeutic success of cetuximab in colorectal cancer (CRC) has demonstrated that the clinical effect of cetuximab is closely dependent not only on KRAS mutations, but also BRAF and phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) mutations. In the present study, the status of KRAS, BRAF and PIK3CA mutations in gastric cancer were investigated concomitantly in order to aid the selection of patients eligible for treatment with cetuximab. Mutations in KRAS (exon 2), BRAF (exon 15) and PIK3CA (exon 9 and exon 20) were retrospectively evaluated by high resolution melting analysis and DNA direct sequencing in samples from 156 patients with gastric cancer. Mutations in either KRAS or PIK3CA were identified in 13 samples (8.3%), 7 samples with KRAS mutations and 6 samples with PIK3CA mutations. No mutations in the BRAF gene were identified. The frequency of mutations in either KRAS or PIK3CA were significantly higher in patients without lymph node metastasis than those with. Furthermore, KRAS and PIK3CA mutations were mutually exclusive. The present study, therefore, suggested that it may be necessary to evaluate KRAS and PIK3CA mutations concomitantly for the selection of patients eligible for treatment with cetuximab.


Gao Z.,Dalian Medical University | Jiang L.-J.,Third Peoples Hospital of Dalian | Xing Y.-Y.,Fourth Peoples Hospital of Shenyang | Wang X.-G.,Dalian Medical University
Journal of Dalian Medical University | Year: 2012

[Objective] To investigate whether pretreatment with flunarizine hydrochlorid could relieve the injury of local cerebral ischemia-reperfusion in rats with hyperglycemia. [Method] Thirty six healthy male SD rats (weight from 180 g to 220 g) were randomly divided into 2 groups: hyperglycemia group (n = 18) and flunarizine + hyperglycemia group (flunarizine group n = 18). The rats in each group were divided into 3 subgroups according to reperfusion 3 h (n = 6), 6 h (n = 6) and 24 h (n = 6) after ischemia for 90 minutes. The differences of cerebral pathological changes and the expressions of ICAM-1 among these groups. [Result] Compared with hyperglycemia group, the number of degenerative and necrosis neurons were less and tissue edema became was weaker. In the flunarizine group, the expression of ICAM-1 can be seen at 3 hours from reperfusion, and increase in 24 hours from reperfusion, P < 0.05. Compared with hyperglycemia group at every reperfusion time: ICAM-1 expressions were decreased in flunarizine group, P < 0.01. [Conclusion] The pretreatment of flunarizine hydrochlorid could decrease the expression of ICAM-1 and the focal ischemia-reperfusion damage of the ras with hyperglycemia.


Feng L.,Dalian Medical University | Li M.,Dalian Medical University | Zhang Q.-P.,Dalian Medical University | Piao Z.-A.,Third Peoples Hospital of Dalian | And 2 more authors.
Oncology Letters | Year: 2011

V-raf murine sarcoma viral oncogene homologB1 (BRAF) is a significant member of the MAPK pathway, the point mutation (V600E) of which is a common genetic event in papillary thyroid carcinoma (PTC). Investigators showed that the variations in BRAF expression levels were independent of the V600E mutation. These variations were involved in the pathogenesis of thyroid carcinomas. This study evaluated the feasibility of BRAF, proliferating cell nuclear antigen (PCNA) and hMSH2 as markers for the prediction of the metastatic potential of PTC. Using immunohistochemistry, the expression of BRAF, PCNA and hMSH2 proteins was studied in 70 PTC and 29 nodular goiter (NG) tissues. The results indicated that i) the positive rate of BRAF, PCNA and hMSH2 expression in PTCs was significantly higher than that in NGs (P=0.000, P=0.000 and P=0.003, respectively), ii) the positive rate of BRAF expression in the lymph node metastasis (LNM) group was significantly higher than that in the non-LNM group (P=0.019), iii) the age at diagnosis of PTC patients with LNM was significantly older compared to that without LNM (P=0.021) and iv) the positive rate of BRAF expression significantly correlated with that of PCNA and hMSH2 expression (P=0.000 and P=0.019, respectively). In conclusion, BRAF, PCNA and hMSH2 overexpression appeared to be molecular events of PTC carcinogenesis. Older patients with BRAF overexpression appear to be a high-risk group for PTC metastasis. Detection of BRAF expression is likely to aid in the prediction of the metastatic potential of the carcinoma.


Liu Y.,Third Peoples Hospital of Dalian | Gong Y.-J.,Dalian Medical University
International Journal of Ophthalmology | Year: 2010

Aim; To learn the up-regulation of aquaporin protein 3 (AQP3) expression in the corneal epithelial healing process of mice by cyclosporin A(CsA) eye drops. Methods; Models were established in the mechanical curettage method of corneal epithelium in mice to observe the repair of corneal epithelium. Corneas were treated with AQP3 immunohistochemical staining to observe the expression of AQP3. Results; AQP3 expression could be seen in the basal cell layer of the cornea. After applications of 125,250,500, 1000mg/L CsA eye drops, the AQP3 expression was increased progressively. When corneal epithelium injury was treated with 500mg/L CsA eye drops, there was no statistical difference in healing size between the experimental group and control group 6 hours after injury, while 12,18,24 hours after injury there was a statistically significant difference (P<0.05). Conclusion: 500mg/L CsA eye drops can accelerate mice corneal epithelial damage repair by increasing the expression of AQP3.


Zhang J.-B.,Third Peoples Hospital of Dalian | Ding Z.-Y.,Capital Medical University | Yang Y.,Third Peoples Hospital of Dalian | Sun W.,Third Peoples Hospital of Dalian | And 6 more authors.
Neurological Research | Year: 2010

Objective: Intravenous administration of recombinant tissue plasminogen activator (rtPA) is known as the only approved treatment for acute ischemic stroke. However, it is still controversial whether acute ischemic stroke patients with atrial fibrillation should receive rtPA therapy. Methods: We studied 99 patients altogether who belonged to three different groups based on the patient characteristics: (1) atrial fibrillation rtPA-treated group consisting of 22 ischemic stroke patients with atrial fibrillation treated with rtPA within 4·5 hours after the onset of stroke; (2) atrial fibrillation non-rtPA-treated group consisting of 44 acute ischemic stroke patients with atrial fibrillation matching in age and baseline National Institutes of Health Stroke Scale (NIHSS); (3) the non-atrial fibrillation rtPA-treated group consisting of 33 patients without atrial fibrillation treated with rtPA. Results: The median time for the administration of rtPA was 199·6 ± 50·0 minutes. More patients had favorable outcomes (90 day modified Rankin Scale 0-1) in the atrial fibrillation rtPA-treated group than the atrial fibrillation non-rtPA-treated group (36·4 versus 13·6%; odds ratio=2·667; 95% confidence interval: 1·056-6·735; p=0·033). The mortality at day 90 was lower in the rtPA-treated group than the non-rtPA-treated group (18·2 versus 20·5%; p=0·827), although the incidence of symptomatic intracranial hemorrhage was higher (18·2 versus 6·8%; p=0·184). Patients in the atrial fibrillation rtPA-treated group had fewer favorable outcomes than non-atrial fibrillation rtPA-treated group (36·4 versus 51·6%; p=0·076), but their baseline NIHSS was higher (12·0 ± 7·1 versus 9·1 ± 7·3; p=0·161). Conclusion: As compared with non-rtPA-treated patients, rtPA treated within 4·5 hours after the onset of stroke significantly improved clinical outcomes in atrial fibrillation patients. Thrombolytic treatment increases intracranial hemorrhage rate but does not increase mortality. © 2010 Maney Publishing.


Bo L.V.,Third Peoples Hospital of Dalian
Journal of Dalian Medical University | Year: 2013

Objective To observe the therapeutic effect of Insulin Aspart 30 combined with Voglibose in treating type 2 diabetes mellitus. Methods 80 patients with type 2 diabetes mellitus were randomly divided into two groups. 40 patients in control group were treated with Insulin Aspart 30 and the other patients in observation group were treated with Insulin Aspart 30 combined with Voglibose, with a treatment course of 2 weeks for both groups. Fasting blood glucose( FBG) , 2 hours postprandial blood glucose (2hPBG) , daily dosage of insulin and incidence of hypoglycemia were detected after treatment. Results After 2 weeks, the 2hPBG was (8. 39 ± 1.88) mmol/L, (8. 21 ± 1.55 ) mmol/L, (8. 12 ± 1.65 ) mmol/L respectively in observation group and (9.70 ±1.71) mmol/L, ( 10.32 ± 1.43 ) mmol/L, (9. 88 ± 1.54) mmol/L respectively in control group. Insulin daily dosage was (35.0±9.5)U in observation group and (46.5 ±10.2)U in control group. There were 9 hypoglycemic events in control group and 2 in observation group. So the 2hPBG, insulin daily dosage and incidence of hypoglycemia between the two groups were statistically significant (P <0.05). There were no statistical difference in the FBG between the two groups (P>0.05). Conclusion Insulin Aspart 30 combined with Voglibose is proved to be a safe and effective therapy for type 2 diabetes mellitus with lower insulin dosage and incidence of hypoglycemia.

Loading Third Peoples Hospital of Dalian collaborators
Loading Third Peoples Hospital of Dalian collaborators